Technologies pad offerings for detection and screening of new drugs, radiolabeling, and bead-based assays.

PerkinElmer has purchased the assets of GE Healthcare’s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay (SPA) reagents, and Cytostar-T plate product lines.

The Catalog Radiochemical products are used for a variety of research applications including screening of potential drug candidates through binding assays. The SPA bead-based, light-emitting assay and Cytostar-T plate technologies enable the automation of high-throughput screening (HTS) processes.

“We expect that the incorporation of these technologies will strengthen our industry-leading GPCR and kinase research product lines and complement our HTS and research reagent solutions,” says Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer.

PerkinElmer plans to continue expanding its NEN® radiochemical portfolio. The company’s solutions in radiometric detection include lines of readers, nuclear counters, and other instrumentation.

Previous article3-D Cerebral Cortex Model
Next articleSpecial Report: Biogen Idec and Facet—Following the Money